A recent first-in-human study showed no detectable signal in the basal ganglia and brainstem, suggesting high binding selectivity of these tracers to tau deposition in patients with AD (Villemagne, 2017; Lohith et al., 2018; Wong et al., 2018). Here, MAPT is linked to Alzheimer disease.